As of 18th Feb, we'll no longer be posting updates here. Instead, we're focusing on platforms that better align with our mission to foster inclusive collaboration, diversity, equity & trust among metastasis researchers worldwide. Connect with us here: https://t.co/WKUxtsNGfv
Advocates! @CancerResrch's advocate focused virtual event that provides a deeper dive into our discussions from last week's diagnostics meeting is February 19!
Register today and share your questions - we'd love to answer them during the event!
https://t.co/NJINrVMez5
5/What were your goals as MRS president? 👩🏿🔬👨🏽����👩🏻🔬
To make MRS more welcoming to scientists and clinicians interested in metastasis research, promote junior researchers, enhance ties with patient advocacy groups such as @metavivor and @SusanGKomen, and strengthen our finances.
4/...My favorite project is our study of Metadherin (MTDH) which is a classic example of cancer fitness genes and ideal therapeutic target to prevent or reduce metastatic cancers.
https://t.co/gMgcA5e7wY
3/What is your research focus area? 🧬🔬
Our research focuses on tumor cell-intrinsic mechanism (cancer fitness genes) and stromal elements (stromal niche) that relieve the stresses tumor cells encounter during tumor progression and metastasis...
2/When did you first get involved with the MRS? 🌍
In 2004, when transitioning from my postdoc at MSKCC to my faculty position at Princeton University, Danny Welch invited me to give a talk at the 10th MRS meeting in Genoa, Italy. I have been an active MRS member ever since.
Meet the presidents! Dr. Yibin Kang @yibinkang is the Warner-Lambert/Parke-Davis Professor of Molecular Biology @Princeton and served as the Metastasis Research Society’s president from 2016-2018.
We interviewed Dr. Kang about his research and involvement with the society 🧵...
Registration is now OPEN for the cancer research community to join us for the EACR 2025 Congress! 🥳
Don't miss the opportunity to take advantage of our discounted early registration rate to attend, available until 28 April.
https://t.co/NgD4KSuxM5
7/Epigenetic states define disseminated tumor cell (DTC) fate. In this study, the authors find that hypomethylated DTCs respond to WNT ligands, extravasate and undergo dormancy, while methylated DTCs proliferate intravascularly.
@moviqu@HellmutAugustin
https://t.co/3KMghatTld
1/Happy new year from the Metastasis Research Society!
As we close out 2024, here are some additional studies that have shaped our understanding of metastasis biology this year. 🧵...
6/Timing of pancreas cancer metastasis. By profiling patient samples, the authors reveal immune remodeling in the pre-metastatic liver and propose liver sampling to determine pancreas cancer metastatic propensity.
David Lyden @WeillCornell
https://t.co/zKfcvNMxMS
7/Uncover the immune landscape of metastatic niches. This study maps single-cell profiles, identifying TREM2+ regulatory macrophages at invasive margins as drivers of immune evasion.
@IdoYofe@IdoAmitLab
https://t.co/qu8MLAUbCI
1/2024 was a big year for metastasis research! Check out our top articles on metastasis research from this year below. The field is driving progress and promise for patients with metastatic cancer.
Join MRS for monthly updates on all things metastasis:
https://t.co/YqlHmv5EvT
6/Learn how immune cells in the lungs suppress breast cancer metastasis. This study shows alveolar macrophages induce metastatic dormancy via TGF-β2 signaling, offering new therapeutic insights.
@EriDalla@micpapanicolaou@MiriamMerad @JAguirreGhiso
https://t.co/Z4T2MwTR0l